Next-generation replication-defective HSV vectors for delivery of large DNA payloads

Area of Science:

• Gene therapy
• Viral vector technology
• Molecular biology

Background:

• Gene therapy for complex diseases requires delivering large genetic payloads (>10 kbp), which current vectors like AAVs and lentiviruses cannot efficiently accommodate.
• Many genetic disorders, including neurodegenerative and inflammatory diseases, necessitate large genes or complex genetic elements for correction.
• Effective gene therapy demands precise regulatory control over transgene expression, including specificity, timing, and duration.

Purpose of the Study:

• To review next-generation replication-defective herpes simplex virus (rdHSV) vectors as a solution for large payload gene delivery.
• To highlight the potential of rdHSV vectors for treating complex genetic diseases affecting various tissues, particularly neurons.
• To discuss the engineering of rdHSV vectors for safe, long-term, and precisely regulated transgene expression.

Main Methods:

• Exploration of replication-defective herpes simplex virus (rdHSV) mutants that lack essential viral gene products.
• Analysis of rdHSV vector systems engineered for high payload capacity and minimal viral gene expression.
• Review of strategies for achieving safe, long-term, and regulated transgene expression using rdHSV vectors.

Main Results:

• Next-generation rdHSV vectors possess high payload capacity, exceeding limitations of common viral vectors.
• These rdHSV vectors can be engineered to express transgenes without producing viral proteins, enhancing safety.
• rdHSV vectors facilitate precise regulatory control over transgene expression, crucial for complex gene therapies.
• The technology enables the delivery of large or intricate genetic payloads for potential treatment of neurodegenerative and inflammatory diseases.

Conclusions:

• Replication-defective herpes simplex virus (rdHSV) vectors represent a promising advancement in gene therapy vector technology.
• Their high payload capacity and engineered safety features make them suitable for addressing complex genetic diseases.
• rdHSV vectors offer a viable strategy for large or intricate gene replacement therapies, potentially revolutionizing treatment for currently intractable conditions.